Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native SCGB1A1 protein in patients. We are developing a pharmaceutical therapy to replace SCGB1A1 with the synthetic version (Therabron™) in respiratory diseases characterized by inflammation and pre-existing SCGB1A1 deficiency.
Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring SCGB1A1 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. Unlike many treatments that provide symptomatic treatment only, Therabron™ has the potential to impact the underlying disease process, or to help resolve inflamed airways in a wide range of respiratory conditions such as persistent sinusitis, bronchiolitis obliterans (a type of pulmonary fibrosis) in lung and hematopoitetic cell transplant recipients, and acute lung injury such as that due to smoke inhalation.
Three Phase 1 and 2 clinical trials with Therabron™ have been completed and Trove aims to perform a Phase 2 trial in adults with chronic sinusitis, who are knwon to lack sufficient native SCGB1A1 in their nasal epithelium. We are developing Therabron™ to replace native SCGB1A1 in an effort to potentially benefit a range of respiratory conditions characterized by inflammation and native SCGB1A1 deficiency.
Trove Therapeutics, Inc. is a Delaware biotechnology corporation headquartered in Rockville, Maryland.